Novocure Ltd (NVCR)

[dstock07734]

The selling records of the NVCR managment. Pay special attention to the amount of money they made after May 28, 2018 on which the first results from p3 trial of DCVax-L were published. It seems to me every management crew of NVCR is ready to abandon the ship.

Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide.

Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.

Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012.

Mr. Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.

Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development.

Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer.

Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.

Gabriel Leung has been Vice Chairman and a director of Novocure since 2011.


Todd Longsworth joined Novocure in 2012 and serves as General Counsel.

Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.


https://investorshub.advfn.com/uimage/uploads/2023/7/30/iqylhAsaf_Danziger_NVCR.png